Kush Parmar
Kush Parmar's purchase track record
Kush Parmar has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/2/2021 | TRDA | $5.00M | -59.8% | -74.6% | -9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Vor Biopharma Phase 3 data draws valuation focus. Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.
Transaction History
| TRDA | ▼ Sell | Open Market | 92,444 | $647K | 8/10/2026 | View on chart |
| TRDA | ▼ Sell | Open Market | 52,317 | $358K | 8/7/2026 | View on chart |
| TRDA | ▼ Sell | Open Market | 10,494 | $73K | 8/6/2026 | View on chart |
| TRDA | ▼ Sell | Open Market | 1,718 | $12K | 7/31/2026 | View on chart |
| TRDA | ▼ Sell | Open Market | 114,756 | $795K | 7/30/2026 | View on chart |
| TRDA | ▼ Sell | Open Market | 200,000 | $1.8M | 11/14/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 6,935 | $52K | 7/9/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 20,065 | $151K | 7/9/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 6,422 | $46K | 7/1/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 18,578 | $132K | 7/1/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 18,578 | $127K | 6/30/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 6,422 | $44K | 6/30/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 55,735 | $385K | 6/27/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 19,265 | $133K | 6/27/2025 | View on chart |
| RLYB | ▼ Sell | Open Market | 100,000 | $820K | 3/7/2023 | View on chart |
| RLYB | ▼ Sell | Open Market | 99,671 | $1.2M | 6/3/2022 | View on chart |
| RLYB | ▼ Sell | Open Market | 50,329 | $629K | 6/3/2022 | View on chart |
| RLYB | ▼ Sell | Open Market | 66,447 | $864K | 5/23/2022 | View on chart |
| RLYB | ▼ Sell | Open Market | 33,553 | $436K | 5/23/2022 | View on chart |
| RLYB | ▼ Sell | Open Market | 139,539 | $1.8M | 2/8/2022 | View on chart |
| RLYB | ▼ Sell | Open Market | 70,461 | $920K | 2/8/2022 | View on chart |
| VOR | ▼ Sell | Open Market | 238,870 | $3.7M | 11/16/2021 | View on chart |
| VOR | ▼ Sell | Open Market | 91,836 | $1.4M | 11/16/2021 | View on chart |
| TRDA | ▼ Sell | Other | 254,512 | — | 11/2/2021 | View on chart |
| TRDA | ▼ Sell | Other | 318,140 | — | 11/2/2021 | View on chart |
| TRDA | ▲ Buy | Open Market | 250,000 | $5.0M | 11/2/2021 | View on chart |
| TRDA | ▼ Sell | Other | 564,217 | — | 11/2/2021 | View on chart |
| TRDA | ▼ Sell | Other | 2,371,739 | — | 11/2/2021 | View on chart |
| TRDA | ▼ Sell | Other | 318,616 | — | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TRDA sees institutional interest from NVIDIA and Merck
The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.
TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.